Heptad-repeat-2 mutations enhance the stability of the enfuvirtide- resistant HIV-1 gp41 hairpin structure

Antiviral Therapy

Volumn 10, Issue 8, 2005, Pages 893-900

  Jenwitheesuk, Ekachai ^a   Samudrala, Ram ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ENFUVIRTIDE; GLYCOPROTEIN GP 41; MUTANT PROTEIN;

AMINO ACID SUBSTITUTION; ANALYTIC METHOD; ARTICLE; COMPLEX FORMATION; DRUG PROTEIN BINDING; HUMAN IMMUNODEFICIENCY VIRUS 1; MELTING POINT; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; PROTEIN STRUCTURE; RELIABILITY; RESIDUE SPECIFIC ALL ATOM PROBABILITY DISCRIMINATORY FUNCTION; THEORETICAL MODEL; VIRUS MUTATION; VIRUS RESISTANCE; WILD TYPE;

DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; MODELS, CHEMICAL; MUTATION; PEPTIDE FRAGMENTS;

EID: 30444438557     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Wyatt R & Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998: 280:1884-1888.
2. Chan DC & Kim PS. HIV entry and its inhibition. Cell 1998; 93:681-684.
3. Weissenhorn W, Dessen A, Calder LJ, Harrison SG, Skehel JJ & Wiley DC. Structural basis for membrane fusion by enveloped viruses. Molecular Membrane Biology 1999; 16:3-9.
4. Wild C, Oas T, McDanal C, Bolognesi D & Matthews T. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proceedings of the National Academy of Sciences of the United States of America 1992; 89:10537-10541.
5. Jiang S, Lin K, Strick N & Neurath AR. HIV-1 inhibition by a peptide. Nature 1993; 365:113.
6. Wild C, Greenwell T & Matthews T. A synthetic peptide from HlV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Research and Human Retroviruses 1993; 9:1051-1053.
7. Wild C, Shugars D, Greenwell T, McDanal C & Matthews T. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proceedings of the National Academy of Sciences of the United States of America 1994; 91:9770-9774.
8. Roman F, Gonzalez D, Lambert C, Deroo S, Fischer A, Baurith T, Staub T, Boulme R, Arendt V, Schneider F, Hemmer R & Schmit JC. Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains. Journal of Acquired Immune Deficiency Syndromes 2003; 33:134-139.
9. Marcelin AG, Reynes T, Yerly S, Ktorza N, Segondy M, Piot JC, Delfraissy JF, Kaiser L, Perrin L, Katlama C & Calvez V. Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20. AIDS 2004; 18:1340-1342.
10. Wei X, Decker JM Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM & Kappes JC. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrobial Agents and Chemotherapy 2002; 46:1896-1905.
11. Lu J, Sista P. Giguel F, Greenberg M & Kuritzkes DR. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). Journal of Virology 2004; 78:4628-4637.
12. Menzo S, Castagna A, Monachetti A, Hasson H, Danise A, Carini E, Bagnarelli P, Lazzarin A & Clementi M. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrobial Agents and Chemotherapy 2004; 48:3253-3259.
13. Caffrey M. Model for the structure of the HIV gp41 ectodomain: insight into the intermolecular interactions of the gp41 loop. Biochimica et Biophysica Acta 2001; 1536:116-122.
14. Bower M, Cohen FE & Dunbrack RL Jr. Prediction of protein side-chain rotamers from a backbone-dependent rotamer library: a new homology modeling tool. Journal of Molecular Biology 1997; 267:1268-1282.
15. Levitt M & Lifson S. Refinement of protein conformations using a macromolecular energy minimization procedure. Journal of Molecular Biology 1969; 46:269-279.
16. Levitt M. Energy refinement of hen egg-white lysozyme. Journal of Molecular Biology 1974; 82:393-420.
17. Levitt M. Molecular dynamics of native protein. Journal of Molecular Biology 1983; 168:595-620.
18. Levitt M, Hirshberg M, Sharon R & Daggett V. Potential energy function and parameters for simulations of the molecular dynamics of proteins and nucleic acids in solution. Computer Physics Communications 1995; 91:215-231.
19. Samudrala R & Moult J. An all-atom distance dependent conditional probability discriminatory function for protein structure prediction. Journal of Molecular Biology 1997; 275:895-916.
20. Hung LH, Ngan SC, Liu T & Samudrala R. PROTINFO: new algorithms for enhanced protein structure predictions. Nucleic Acids Research 2005; 33:77-80.
21. Sanders RW, Vesanen M, Schuelke N, Master A, Schiffner L, Kalyanaraman R, Paluch M, Berkhout B, Maddon PJ, Oison WC, Lu M & Moore JP. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. Journal of Virology 2002; 76:8875-8889.
22. Markosyan RM, Ma X, Lu M, Cohen FS & Melikyan GB. The mechanism of inhibition of HIV1 env-mediated cell-cell fusion by recombinant cores of gp41 ectodomain. Virology 2002; 10:302:174-184.
23. Greenberg ML & Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. The Journal of Antimicrobial Chemotherapy 2004; 54:333-340.
24. Gallo SA, Sackett K, Rawat SS. Shai Y & Blumenthal R. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors. Journal of Molecular Biology 2004; 340:9-14.